Dramatic advances in the fields of biochemistry, cell and molecular biology, genetics, biomedical engineering and materials science have given rise to the remarkable new cross-disciplinary field of tissue engineering. Tissue engineering uses synthetic or naturally derived, engineered biomaterials to replace damaged or defective tissues, such as bone, skin, and even organs.
Transplanting autologous renal progenitor cells, into rat models with kidney damage from pyelonephritis - a type of urinary infection that has reached the kidney - has been found to improve kidney structure and function.
bioMD Limited (ASX: BOD), a company with assets in regenerative tissue engineering technologies today announced that it has made an offer to buy all of the shares in Allied Medical Limited (Allied), a public unlisted company that specialises in the sales, distribution and commercialisation of medical technologies.
BioTime, Inc., a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine, today announced it has signed a definitive agreement to merge Utah-based Glycosan BioSystems, Inc. (Glycosan) with BioTime's wholly-owned subsidiary, OrthoCyte Corporation. The acquisition is expected to close by March 18, 2011.
Harvard Bioscience, Inc., a global developer, manufacturer and marketer of a broad range of specialized products used to advance life science research and regenerative medicine, is pleased to announce that its novel bioreactor technology was featured on the National Geographic Channel's Explorer television program on February 7, 2011.
The University of South Florida received $5.45 million in grants from the Bill & Melinda Gates Foundation. The first grant is to create advanced devices that mimic the human liver to better study the life cycle of the malaria parasite - particularly the elusive liver stage where the disease may be most vulnerable to attack.
Tufts University today announced the public launch of the Tufts Institute for Biomedical Partnerships website/HUB: www.tuftspharmapartners.org.
Scientists from USA have developed a method to produce a ready made supply of blood vessels for use in heart bypass surgery. A study on baboons and dogs reported in journal Science Translational Medicine suggests vessels could be stored for up to a year and used by any patient. These vessels have been grown earlier from a patient’s own cells, but this takes several months.
Arteriocyte, a leading clinical stage biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts that develops proprietary stem cell and tissue engineering based therapies, announced today approval from the Food and Drug Administration to initiate a Phase I clinical trial using its Magellan MAR01 technology in the treatment of Critical Limb Ischemia.
XYTOS Shares Patient Results.
A new study reports on the success of growing human liver cells on resorbable scaffolds made from material similar to surgical sutures. Researchers suggest that this liver tissue could be used in place of donor organs during liver transplantation or during the bridge period until a suitable donor is available for patients with acute liver failure.
Skin cells from a patient with an inherited heart disease were the seeds of a stem cell experiment that could help researchers test specific treatments for the disease, known as long QT syndrome. The research results appear in the January 16 issue of the journal Nature.
Research by engineers and cancer biologists at Virginia Tech indicate that using specific silicon microdevices might provide a new way to screen breast cancer cells' ability to metastasize.
Research by engineers and cancer biologists at Virginia Tech indicate that using specific silicon microdevices might provide a new way to screen breast cancer cells' ability to metastasize.
New technologies and methods are spurring a renaissance in the study of organogenesis. Organogenesis, essentially the process through which a group of cells becomes a functioning organ, has important connections to biological processes at the cellular and developmental levels, and its study offers great potential for medical treatments through tissue engineering approaches.
Researchers from Cornell University and Weill Cornell Medical College have been awarded $100,000 by NFL Charities, the charitable foundation of the National Football League owners, to research tissue engineering for spinal injuries.
Nutritional supplementation with Spirulina, a nutrient-rich, blue-green algae, appeared to provide neuroprotective support for dying motor neurons in a mouse model of amyotrophic lateral sclerosis, also known as Lou Gehrig's disease, University of South Florida neuroscientists have found.
Organovo, Inc., a regenerative medicine company focused on bioprinting technology, today announced the release of data on the first fully bioprinted blood vessels. Data was presented at the Tissue Engineering and Regenerative Medicine International Society (TERMIS) meeting in Orlando, Florida. The blood vessels were created through the use of the NovoGen MMX Bioprinter, Organovo's proprietary platform for the creation of 3D tissue constructs.
Arteriocyte, Inc., a leading clinical stage biotechnology company with offices in Cleveland, Ohio, and Hopkinton, Massachusetts, that develops proprietary stem cell and tissue engineering based therapies announced today the launch of its first commercially available Stem Cell Expansion System for research use.
Breast cancers that arise sporadically, rather than through inheritance of certain genes, likely start with defects of DNA repair mechanisms that allow environmentally triggered mutations to accumulate, according to researchers at the University of Pittsburgh School of Medicine, Magee-Womens Hospital of UPMC and the University of Pittsburgh Cancer Institute.
Coatings functionalize surfaces or protect them from processes such as corrosion, abrasion, and weathering, and may provide an aesthetic appearance—automotive coatings and non-stick frying pans are good examples. Contact lenses, implants, LEDs, or photovoltaic cells require extremely thin coatings. In the journal Angewandte Chemie, the teams led by Gero Decher at the Institut Charles Sadron in Strasbourg (France) have now introduced a new process for the production of ultrathin coatings that is especially simple, versatile, and suitable for large-scale processes.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.